yvandenbroek
/
sprookjes
/
Login
Register
TriplyDB
sprookjes
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q34344198-2E1239AE-2C5D-440B-8673-BC44951D69BF
Q34344198-2E1239AE-2C5D-440B-8673-BC44951D69BF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34344198-2E1239AE-2C5D-440B-8673-BC44951D69BF
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer.
P2860
Q34344198-2E1239AE-2C5D-440B-8673-BC44951D69BF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34344198-2E1239AE-2C5D-440B-8673-BC44951D69BF
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4aa832b54a25d5065469c62f6fa321bf2c3c010c
P2860
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.